SPIRITT Research Becomes Latest CRO to Join MedNet Solutions' iMedNet Partner Program
SPIRITT Selects iMedNet EDC for its eClinical Flexibility and Ease of Use
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is pleased to announce that SPIRITT Research, a boutique research services organization with a passion for improving patient treatment outcomes and quality of life, has joined MedNet’s iMedNet Partner Program. SPIRITT will leverage iMedNet EDC, MedNet’s flagship eClinical solution, to get their research studies set up quickly, easily and cost-effectively.
“SPIRITT is an ideal partner for MedNet, given our companies’ deep, shared expertise supporting orthopedic and spine related research, as well as post market studies and registries,” remarked John M. (Rob) Robertson, President and CEO of MedNet Solutions. “We’re confident that our organizations will work very well together and that iMedNet EDC will provide SPIRITT with the technology infrastructure they need to facilitate effective and efficient research.”
“We are very pleased to be partnering with MedNet Solutions,” commented Francine Schranck, President of SPIRITT. “The iMedNet product is one of the best clinical trial management systems we’ve seen, and we recommend it without reservation.”
Matthew Britt, Director of Clinical Affairs at SPIRITT, added, “We are asked all the time by our clients about the best solutions to support them in their various clinical trials, and because of its flexibility and ease of use, iMedNet is a logical choice.”
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
